Cranford, New Jersey -- August 17, 2023 -- Marker Therapeutics (NASDAQ: MRKR) highlights its technology during a recently held, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient's own T cells to fight cancer.
During the Webinar, Dr. Juan Vera, President and CEO of Marker, describes his company’s progress in advancing novel T cell therapies for blood cancers and solid tumors. He said, “ Marker envisions its multiple tumor-associated antigen (multiTAA) targeted therapy will be superior to treatment approaches targeting a single antigen, such as CAR-T cells.” He further reported that “Marker’s MT-601 product candidate demonstrated non-clinical evidence of anti-tumor activity in CAR-T cell resistant lymphoma cells.”
Featured in the first part of this two-part Webinar are two physician scientists on the frontier of this emerging medical technology - Doctors Helen Heslop and Malcolm Brenner from the Center for Cell and Gene Therapy at Baylor College of Medicine. They describe the current state of CAR-T therapy and ongoing research to enhance CAR-T and off-the-shelf cell therapies that can be used to treat many forms of cancer.
Segment One begins with an introduction by Steve Brozak, CEO of WBB Securities and founder of WBB Research Institute, followed with a video presentation by Dr. Heslop, describing the current state of CAR-T cell technology, clinical applications, and potential markets. Following the video, Dr. Brenner describes an approach to using CAR-T therapy for treating solid tumors, saying we need “an approach that deals with a tumor holistically, and one of the ways it might be possible to do that is by focusing not so much on the proteins that those tumors express but also on the whole tumor glycan (matrix).”
During the second segment of the Webinar, Dr. Vera reports Marker’s advances in novel T cell therapies for blood cancers and solid tumors. He is joined by Dr. Mark Frohlich of Indapta Therapeutics, who describes both company’s efforts to develop an off-the-shelf cell therapy to treat cancer.
Commenting on the Webinar Dr. Vera concluded “The diverse perspectives fueled a lively discussion in which we shared cutting-edge research and technological advancements that are shaping the future in the field. It was exciting to discuss the prospects for immunotherapies, and although many things are still uncertain, it is clear to us that Marker Therapeutics will play a pivotal role in the future of immuno-oncology.”
For further information, visit wbbsec.com/wbb-research-institute
The WBB Research Institute is a research organization, founded by WBB Securities. The Institute focuses on emerging critical issues in healthcare that threaten to have profound impact. WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused on the life sciences. WBB Securities is registered with the SEC as a broker-dealer, a FINRA member firm, and a Registered Investment Advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.
